• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Tadalis Teva
    / Teva


    Active Ingredient
    Tadalafil 20 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    1 X 20 mg

    partial basket chart 55631

    Tablets

    4 X 20 mg

    partial basket chart 55633

    Tablets

    8 X 20 mg

    partial basket chart 55632

    Related information


    Dosage

    The recommended starting dose is 10 mg (half of the product’s 20 mg tablet) before sexual activity. If the effect of this dosage is too weak, an increased dose of 20mg tadalafil can be taken. This medicinal product should be taken at least 30 minutes before sexual activity. Not more than one tablet a day. May be taken at any time during the day. The effect may last up to 36 hours. Since the effect is maintained for more than one day, not for daily use.


    Indications

    Tadalis Teva is intended for the treatment of erectile dysfunction in men, for obtaining and maintaining an erection.


    Contra-Indications

    Hypersensitivity to the active substance or to any of the excipients.
    Administration of tadalafil to patients who are under any form of organic nitrate therapy.
    Men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease.
    The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated:
    Patients with myocardial infarction within the last 90 days.
    Patients with unstable angina or angina occurring during sexual intercourse.
    Patients with New York Heart Association Class 2 or greater heart failure in the last 6 months.
    Patients with uncontrolled arrhythmias, hypotension (<90/50 mmHg), or uncontrolled hypertension.
    Patients with a stroke within the last 6 months.
    Tadalafil is contraindicated in patients who have loss of vision in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure.
    The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension.


    Special Precautions

    Please refer to the license holder for further details.


    Side Effects

    Please refer to the license holder for further details.


    Manufacturer
    Teva Pharmaceutical Industries Ltd, Israel
    CLOSE